Bull case
Eloxx Pharma is attractive because exaluren targets a biologically validated mechanism—premature stop-codon readthrough—with precedent across Duchenne’s, epidermolysis bullosa, cystic fibrosis, and Alport, while its ~290x cytoplasmic-versus-mitochondrial ribosome selectivity and clean safety profile across 145 subjects reduce the toxicity overhang that hurt earlier aminoglycosides. The company’s lead Alport program has already shown structural activity in 3 patients, including improved podocyte foot processes, collagen IV, and GBM measures, and the ongoing randomized EXACT study is better positioned to confirm whether those biopsy signals translate into meaningful proteinuria and functional benefit over 16 and 32 weeks. Fundamentally, the stock offers asymmetric upside because it is the only mutation-directed therapy in clinical development for NMAS, carries a sizable ADPKD follow-on opportunity, and had $62M in cash as of 2Q26, supporting execution into mid-2028.